English 
Cala Health Secures $50M to Expand Tremor Therapy
Cala Health, a California-based bioelectronic medicine company, has raised $50 million in an oversubscribed growth funding round. The funds will help expand its FDA-cleared TAPS therapy, a wearable solution for essential tremor patients.
Funding Details
Investors Involved:
The funding round was co-led by Vertex Growth Fund and Nexus NeuroTech Ventures, with participation from existing investors, including:
- Johnson & Johnson Innovation
- GV (Google Ventures)
- Lux Capital
- Action Potential and others.
The strong backing underscores growing investor confidence in Cala Health’s innovative tremor therapy solutions.
What Is Cala TAPS Therapy?
Cala Health specializes in wearable neuromodulation technology for chronic diseases. Its flagship product, the Cala kIQ System, addresses essential tremor through transcutaneous afferent patterned stimulation (TAPS) therapy.
Key Features:
- FDA-Cleared: Provides non-invasive tremor relief.
- On-Demand Therapy: Allows users to manage tremors when needed.
- Data Insights: Offers users the ability to track progress over time.
Essential tremor affects millions globally, causing involuntary shaking that disrupts daily life. Cala’s wearable device offers a cutting-edge, drug-free alternative.
What’s Next for Cala Health?
The $50 million funding will support:
- Commercial Expansion: Accelerating the rollout of TAPS therapy, especially after a positive Medicare Coverage Determination.
- Awareness Building: Enhancing visibility among patients and healthcare providers.
- Broader Reach: Expanding access to its technology for essential tremor patients.
“We’re thrilled with the strong support from new and existing investors who believe in our vision to revolutionize tremor relief with on-demand, wearable technology,” said Deanna Harshbarger, CEO of Cala Health.
Conclusion
Cala Health’s $50M funding marks a pivotal moment for wearable medical technology. By scaling its TAPS therapy, Cala aims to transform tremor treatment, empowering patients with effective, non-invasive solutions.
